| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
2 companies
James E. Levine is Chief Financial Officer at CRDF and has filed Form 4s across 2 companies. James E. Levine's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $159K at current prices.
Historically, James E. Levine's trades have earned a below-average insider score of 31/100 across 5 rated trades. Over a 12-month horizon, 20.0% of those trades were profitable, with an average 12-month return of -36.8%.
The biggest single holding is CDTX (~$101K) as Chief Financial Officer. Net of sales, the CDTX filings show accumulation of 80,000 shares.
James E. Levine has 15 Form 4 filings on record from December 2018 to June 2026, across 3 companies: Chief Financial Officer at Kazia Therapeutics (KZIA), 2026; Chief Financial Officer at Cardiff Oncology (CRDF), 2021–2025; Chief Financial Officer at CDTX, 2018–2021.
The 21 reported transactions were 11 open-market purchases, 8 option or other derivative awards, 1 stock award and 1 option exercise.
Counted by filing, the open-market trades come to 5 purchases worth about $435K and no sales.
The largest open-market purchase was 30,000 shares of CRDF at an average $6.47 on September 10, 2021, about $194K. Twelve months later CRDF was down 54%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 18, 2024 | CRDF Cardiff Oncology, Inc. | Chief Financial Officer | Buy | 7,716 | $4.76 | $36,725.50 | +12.9% | -15.6% | -44.3% | |
| Sep 16, 2022 | CRDF Cardiff Oncology, Inc. | Chief Financial Officer | Buy | 30,000 | $1.56 | $46,710.00 | +100.0% | -11.4% | +9.5% | |
| Sep 10, 2021 | CRDF Cardiff Oncology, Inc. | Chief Financial Officer | Buy | 30,000 | $6.47 | $194,000.00 | New | -8.3% | -54.0% | |
| Nov 10, 2020 | Chief Financial Officer | Buy | 50,000 | $2.01 | $100,720.00 | New | - | - | ||
| Sep 24, 2019 | Chief Financial Officer | Buy | 30,000 | $1.91 | $57,240.00 | +17.1% | - | - |